Download
https://www.ndtvprofit.com/markets/sun-pharma-fda-regulatory-concerns-at-dadra-facility-can-dent-sentiment-say-analysts?utm_source=telegram&utm_medium=referral&utm_campaign=socialshare
Analysts say that the FDA action at the Dadra unit can push Sun Pharma's stock into a price-wise corrective phase.
Share